CLINICAL TRIALS PROFILE FOR CEPHALEXIN HYDROCHLORIDE

All Clinical Trials for Cephalexin Hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003824 ↗	S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer	Terminated	National Cancer Institute (NCI)	Phase 3	1999-04-01	RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known whether ciprofloxacin is more effective than cephalexin in preventing cancer recurrence in patients who are undergoing surgery to treat bladder cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of ciprofloxacin with that of cephalexin in preventing recurrence of cancer in patients who are undergoing surgery for bladder cancer.
NCT00003824 ↗	S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer	Terminated	Southwest Oncology Group	Phase 3	1999-04-01	RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known whether ciprofloxacin is more effective than cephalexin in preventing cancer recurrence in patients who are undergoing surgery to treat bladder cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of ciprofloxacin with that of cephalexin in preventing recurrence of cancer in patients who are undergoing surgery for bladder cancer.
NCT00179959 ↗	The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis	Completed	Johnson & Johnson	Phase 4	2005-09-01	Staphylococcus aureus (S. aureus) infection is perceived not only as a common secondary complication of atopic dermatitis (AD), but also as a culprit in the worsening of this condition. In addition, the recent development of community acquired methicillin-resistant S. aureus (CA-MRSA) has presented a new challenge to our management of AD, both in treatment of acute infections and maintenance therapy. The investigators would like to perform a randomized investigator-blinded placebo-controlled study of children aged 6 months to 17 years with moderate to severe atopic dermatitis with clinical signs of secondary bacterial infection to study: 1) the prevalence of CA-MRSA in our patient population; 2) the relationship of sensitivity of the S. aureus organism cultured from the infected lesion(s) to clinical response to oral cephalexin therapy and severity of the AD; and 3) whether concurrent treatment of S. aureus infection initially with nasal mupirocin ointment and sodium hypochlorite (bleach) baths can result in long-term S. aureus eradication and clinical stability.
NCT00179959 ↗	The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis	Completed	Society for Pediatric Dermatology	Phase 4	2005-09-01	Staphylococcus aureus (S. aureus) infection is perceived not only as a common secondary complication of atopic dermatitis (AD), but also as a culprit in the worsening of this condition. In addition, the recent development of community acquired methicillin-resistant S. aureus (CA-MRSA) has presented a new challenge to our management of AD, both in treatment of acute infections and maintenance therapy. The investigators would like to perform a randomized investigator-blinded placebo-controlled study of children aged 6 months to 17 years with moderate to severe atopic dermatitis with clinical signs of secondary bacterial infection to study: 1) the prevalence of CA-MRSA in our patient population; 2) the relationship of sensitivity of the S. aureus organism cultured from the infected lesion(s) to clinical response to oral cephalexin therapy and severity of the AD; and 3) whether concurrent treatment of S. aureus infection initially with nasal mupirocin ointment and sodium hypochlorite (bleach) baths can result in long-term S. aureus eradication and clinical stability.
NCT00179959 ↗	The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis	Completed	Northwestern University	Phase 4	2005-09-01	Staphylococcus aureus (S. aureus) infection is perceived not only as a common secondary complication of atopic dermatitis (AD), but also as a culprit in the worsening of this condition. In addition, the recent development of community acquired methicillin-resistant S. aureus (CA-MRSA) has presented a new challenge to our management of AD, both in treatment of acute infections and maintenance therapy. The investigators would like to perform a randomized investigator-blinded placebo-controlled study of children aged 6 months to 17 years with moderate to severe atopic dermatitis with clinical signs of secondary bacterial infection to study: 1) the prevalence of CA-MRSA in our patient population; 2) the relationship of sensitivity of the S. aureus organism cultured from the infected lesion(s) to clinical response to oral cephalexin therapy and severity of the AD; and 3) whether concurrent treatment of S. aureus infection initially with nasal mupirocin ointment and sodium hypochlorite (bleach) baths can result in long-term S. aureus eradication and clinical stability.
NCT00187759 ↗	Placebo Controlled Study of Antibiotic Treatment of Soft Tissue Infection	Completed	University of California, San Francisco	N/A	2004-11-01	This study is to determine whether antibiotic therapy is needed for patients with non-life threatening soft tissue infections. Most patients with these soft tissue infections are presently treated with antibiotics. Many of these infections resolve without proper antibiotic treatment. Treatment of patients with antibiotics after surgical drainage of an abscess may not be necessary and indiscriminate use of antibiotics may lead to colonization by drug-resistant organisms. Subsequent infection by drug resistant organisms may limit the choice of antibiotics in more complicated infections. A comparison between antibiotic treatment and no antibiotic treatment in surgically treated, uncomplicated soft tissue infections is needed to address this very important question.

Clinical Trial Conditions for Cephalexin Hydrochloride

Condition Name

Condition Name for Cephalexin Hydrochloride
Intervention	Trials
Cellulitis	6
Surgical Site Infection	5
Anti-infective Agents	4
Healthy Volunteers	4

Condition MeSH

Condition MeSH for Cephalexin Hydrochloride
Intervention	Trials
Infections	12
Infection	11
Communicable Diseases	9
Surgical Wound Infection	8

Clinical Trial Locations for Cephalexin Hydrochloride

Trials by Country

Trials by Country for Cephalexin Hydrochloride
Location	Trials
United States	74
France	14
Mexico	8
Canada	8
Brazil	3

Trials by US State

Trials by US State for Cephalexin Hydrochloride
Location	Trials
California	8
Pennsylvania	7
Maryland	5
Texas	4
New York	4

Clinical Trial Progress for Cephalexin Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Cephalexin Hydrochloride
Clinical Trial Phase	Trials
PHASE4	1
PHASE1	1
Phase 4	19

Clinical Trial Status

Clinical Trial Status for Cephalexin Hydrochloride
Clinical Trial Phase	Trials
Completed	31
Recruiting	11
Not yet recruiting	7

Clinical Trial Sponsors for Cephalexin Hydrochloride

Sponsor Name

Sponsor Name for Cephalexin Hydrochloride
Sponsor	Trials
Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V.	5
Eli Lilly and Company	5
National Institute of Allergy and Infectious Diseases (NIAID)	3

Sponsor Type

Sponsor Type for Cephalexin Hydrochloride
Sponsor	Trials
Other	94
Industry	21
NIH	6

Cephalexin Hydrochloride: Clinical Trials Update and Market Outlook

Last updated: April 30, 2026

What clinical trials exist for cephalexin hydrochloride?

Cephalexin hydrochloride is an established first-generation cephalosporin. Public clinical activity remains limited relative to newer-generation antibiotics, with most modern evidence consolidated in older trials and post-marketing real-world use. Across major registries, current activity is most commonly reflected through supplemental studies, formulation work, or localized observational research rather than large, new phase-development programs.

Operational implication: For investors and R&D teams, the clinical-trial “signal” for cephalexin is typically driven by:

• Formulation and bioavailability studies (including generic optimization and equivalence)
• Label-expansion studies (narrow indications and dosing regimens)
• Comparative effectiveness and safety monitoring in routine care settings

What this means for interpretation: A sparse pipeline pattern is consistent with a mature, off-patent antibiotic where new trials are often smaller, regulatory-lite, or designed to support generics and incremental label updates.

---

What is the current market landscape for cephalexin?

Cephalexin is widely available globally as an oral and parenteral antibiotic, with broad off-patent competition. Market behavior is dominated by:

• Low unit economics and heavy generic substitution
• Regulatory and procurement contracting rather than premium pricing
• Form factor competition (capsules/tablets vs oral suspensions; immediate vs modified-release where applicable)
• Antibiotic stewardship constraints that limit volume growth even when demand is present

Market structure

• Generic-led: Multiple manufacturers across regions; interchangeability drives commoditization.
• Institutional purchasing: Hospitals and national formularies drive volume.
• Retail channel: Oral cephalexin concentrates where reimbursement is stable.

Pricing and margin profile (typical for mature antibiotics)

Cephalexin’s commercial profile tracks a “commodity antibiotic” pattern: margins compress with increased supply and remain sensitive to procurement cycles, raw material costs, and substitution policy.

---

How large is the cephalexin market and how fast is it growing?

Public market-research datasets often segment cephalosporins broadly rather than isolate cephalexin alone. The dominant practical conclusion for projections is that growth trends track:

• Population and infection incidence
• Formulary access
• Stewardship policies
• Competitive switching across beta-lactams and newer agents

Directional growth expectation for cephalexin (projection framework):

• Base-case: low single-digit growth driven by volume stability and periodic procurement demand
• Upside: stronger growth if stewardship guidance supports low-cost first-generation beta-lactams for defined bacterial populations
• Downside: volume pressure if guidelines shift more use toward other agents due to resistance patterns or availability

Because cephalexin is off-patent in major markets, projection accuracy depends more on share and contracting than on innovation-led demand.

---

What are the key demand drivers and constraints?

Demand drivers

• Broad clinical use for susceptible bacterial infections in common outpatient and inpatient settings.
• Formulary familiarity and wide availability.
• Oral administration as a cost-effective option where appropriate.

Constraints

• Antibiotic stewardship: restrictions on inappropriate use can cap outpatient volumes.
• Resistance epidemiology: beta-lactam susceptibility varies by region and pathogen mix.
• Procurement-driven substitution: formularies may switch between equivalent generics or between different beta-lactams.

---

What regulatory and safety factors influence adoption?

Cephalexin’s regulatory path typically reflects mature labeling and existing safety positioning. Adoption is shaped by:

• Bioequivalence expectations for generics
• Formulation stability requirements for oral suspensions
• Post-market safety monitoring for hypersensitivity, GI adverse events, and rare severe reactions typical to beta-lactams

In practice, safety does not usually create incremental demand; it mainly protects access and constrains adverse-event risk in procurement and prescriber preference.

---

How should investors and R&D teams position for cephalexin going forward?

Best-fit strategies

1. Generic quality and supply reliability
   • Focus on consistent manufacturing, cost-per-dose competitiveness, and stable regulatory standing.
2. Niche formulation differentiation
   • Target dosing convenience (e.g., suspension stability, palatability support) and pediatric usability.
3. Clinical evidence packages for niche label claims
   • Pursue smaller, targeted studies to support specific subpopulations where local guidance supports beta-lactam use.

Where new clinical trials are most likely

• Bioequivalence and bridging studies for different dosage forms
• Small comparative studies tied to local treatment guidelines
• Pharmacokinetic studies in special populations (pediatric, renal impairment) where label updates or local protocol needs exist

---

Market projection: scenarios and business implications

Given the mature, generic-dominated nature of cephalexin, projection is best treated as a share-and-contracting exercise rather than an innovation-led ramp.

Scenario map (directional)

• Base case: steady volume with modest value growth from pricing normalization and contracting cycles.
• Upside case: broader formulary access and stewardship alignment for susceptible infections support incremental share.
• Downside case: stronger substitution by other low-cost beta-lactams and shifting guideline preferences reduce share even if infection incidence is stable.

What to track quarterly

• Tender outcomes and formulary listing changes
• Average selling price by region and channel
• Supply disruptions or raw material swings
• Prescription utilization trends in outpatient settings

---

Key Takeaways

• Cephalexin hydrochloride is mature and generic-led, with clinical activity concentrated in formulation and incremental evidence rather than large new phase programs.
• Market growth is driven mainly by contracting, formulary access, and stable demand for susceptible infections, with stewardship and resistance patterns capping expansion.
• The most practical investment and R&D lens is supply reliability, cost-per-dose, and targeted evidence packages tied to local use patterns.

---

FAQs

1) Is cephalexin hydrochloride still in active clinical development?

Public clinical activity is generally limited and tends to be centered on formulation, bioequivalence, or smaller evidence-generation efforts rather than major innovation-driven phase trials.

2) What drives cephalexin sales in hospital and retail channels?

Hospital purchasing is driven by tender and formulary access. Retail demand depends on prescriber familiarity, reimbursement stability, and patient-level convenience for oral forms.

3) What are the main market risks for cephalexin?

Procurement-driven substitution, stewardship restrictions, and regional resistance patterns that reduce appropriate prescribing.

4) Can new clinical studies expand cephalexin demand?

They can support incremental label or protocol acceptance, but large demand shifts typically require guideline-level changes or major differentiation that is uncommon for mature generics.

5) How should projections be modeled for cephalexin?

Model cephalexin as a mature commodity antibiotic: use scenario-based share and contracting assumptions, and track ASP, tender dynamics, and formulary listing changes.

---

References (APA)

[1] ClinicalTrials.gov. (n.d.). Cephalexin hydrochloride trials. https://clinicaltrials.gov/
[2] U.S. Food and Drug Administration. (n.d.). Drug approvals and labels (cephalexin). https://www.fda.gov/
[3] World Health Organization. (n.d.). Antimicrobial resistance and stewardship resources. https://www.who.int/